Abstract: The disclosure relates to compositions for treating keratin materials. The compositions comprise (a) at least one amphoteric surfactant or a salt thereof; (b) at least one anionic surfactant system comprising (i) at least one acyl taurate, (ii) at least one acyl isethionate, and (iii) at least one additional anionic surfactant; (c) optionally, at least one cationic compound; and (d) sodium chloride, wherein the weight ratio of the (b) at least one anionic surfactant system to (d) sodium chloride ranges from about 1:1 to about 10:1. The disclosure also relates to methods of using the compositions.

Abstract: The disclosure relates to compositions for treating keratin materials. The compositions comprise (a) at least one amphoteric surfactant; (b) at least one anionic surfactant system comprising (i) at least one acyl taurate, (ii) at least one acyl isethionate, and (iii) at least one additional anionic surfactant; (c) at least one nonionic surfactant chosen from alkyl(poly)glycosides; (d) optionally, at least one cationic compound; and (e) sodium chloride, wherein the weight ratio of the (b) at least one anionic surfactant system to (e) sodium chloride ranges from about 5:1 to about 15:1. The disclosure also relates to methods of using the compositions.

Abstract: The invention relates to nail compositions including diisononyl 1,2-cyclohexanedicarboxylate, as well as to methods, kits and nail composition sets related to such compositions.

Abstract: Shampoo composition including about 6 wt. % or more of one or more betaine surfactants; about 5 wt. % or less of one or more anionic surfactants; about 0.1 wt. % to about 10 wt. % of one or more fatty amine surfactants; about 0.1 to about 15 wt. % of one or more nonionic surfactants, wherein at least one of the one or more nonionic surfactants is selected from alkoxylated fatty alcohols, polyethylene glycol ethers of fatty alcohols, or a mixture thereof; and water, wherein all weight percentages are based on the total weight of the shampoo composition. The shampoo compositions typically have a weight ratio of the total amount of the one or more betaine surfactants to the total amount of the one or more anionic surfactants, the one or more fatty amine surfactants, and the one or more nonionic surfactants that is 0.8:1 to 5:1 and are typically substantially free of anionic sulfate surfactants and silicones.

Abstract: The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Abstract: The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.

Abstract: The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The disclosure relates to compositions for cleansing keratin materials. The compositions comprise (a) at least one first amphoteric surfactant chosen from alkyl amphoacetates, alkyl amphodiacetates, salts thereof, or mixtures thereof; (b) at least one second amphoteric surfactant chosen from betaines or salts thereof; (c) at least one nonionic surfactant; (d) at least one non-sulfate anionic surfactant; (e) at least one fatty amine; and (f) at least one polysaccharide thickening agent; wherein the composition is free or essentially free of sulfate-based surfactants and optionally free or essentially free of silicones. The disclosure also relates to methods of using the compositions.

Abstract: Disclosed is a method for deploying tasks in a satellite network. In the method for deploying tasks in a satellite network, a utility function is determined by constructing a task processing delay model and a traffic model; a fitness degree of each individual is determined according to the utility function, and an individual with a highest fitness degree is put into a next-generation population; a probability that each of the plurality of individuals is selected is determined according to the fitness degree; a crossover operation and a mutation operation are performed on the individual according to the probability, to obtain a crossover individual and a mutation individual respectively; an available crossover individual and an available mutation individual are put into a next-generation population, to perform a repeated iteration and complete population updating; an optimal task deployment location table is output; and satellite network task deployment is completed.

Abstract: A method and system for a multi-layer peelable nail cosmetic compositions are disclosed. The multi-layer system includes a water-washable, non-UV curable nail basecoat composition in a hand-held, non-pressurized container. The basecoat composition includes a hydrophilic poly(N-vinyl)lactam polymer, at least one alcohol, and at least one plasticizer. The multi-layer system also includes a colored non-UV curable nail colorcoat composition that includes a primary film former, a secondary film former, a plasticizer, and a colorant.

Abstract: The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: A method and system for a multi-layer peelable nail cosmetic compositions are disclosed. The multi-layer system includes a water-washable, non-UV curable nail basecoat composition in a hand-held, non-pressurized container. The basecoat composition includes a hydrophilic poly(N-vinyl)lactam polymer, at least one alcohol, and at least one plasticizer. The multi-layer system also includes a colored non-UV curable nail colorcoat composition that includes a primary film former, a secondary film former, a plasticizer, and a colorant.

Abstract: The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Abstract: The present disclosure is drawn to nail enamel compositions including cannabis sativa seed oil, and specifically to nail enamel compositions including a plasticizer, a solvent, a film forming polymer, and cannabis sativa seed oil. The plasticizer may be, e.g., a citric acid and/or benzoic acid derivative, and may be present in a total amount of between 1.0% and 10.0% by weight. The solvent may be, e.g., ethyl acetate, propyl acetate, butyl acetate, ethyl lactate, isopropanol, and/or propylene carbonate, and may be present in a total amount of at least 10%. The film forming polymer may include, e.g., a cellulose derivative and/or may include two or more polymers. The film forming polymer may be present in a total amount of between 5.0% and 70.0% by weight. The composition may include a colorant, such as a pigment, and the pigment may be present in an amount of at least 0.5% by weight.

Abstract: The invention presents a fast-drying nail polish topcoat composition with high shine and long wear. The disclosed combination of at least two cellulose-derived primary film formers, a ketone-aldehyde resin, a plasticizer, a hydrocarbon oil, and solvents selected such that no more than 20% of the solvents have an evaporation rate less than or equal to butyl acetate provides a nail polish that can be dried within 30 seconds on fingernails without sacrificing other critical properties.

Abstract: The invention presents a fast-drying nail polish topcoat composition with high shine and long wear. The disclosed combination of at least two cellulose-derived primary film formers, a ketone-aldehyde resin, a plasticizer, a hydrocarbon oil, and solvents selected such that no more than 20% of the solvents have an evaporation rate less than or equal to butyl acetate provides a nail polish that can be dried within 30 seconds on fingernails without sacrificing other critical properties.

Abstract: The invention presents a fast-drying nail enamel composition with good stability, easy application, high shine and long wear. The disclosed combination of an acrylic resin having a Tg greater than a threshold temperature; a second resin having a Tg less than the threshold temperature; at least one plasticizer selected from the group consisting of a benzoic acid derivative, a citric acid derivative, and an isobutyrate derivative; a non-polar silicone copolymer; and at least one solvent having an evaporation rate greater than butyl acetate provides a nail polish that can be dried within 40-60 seconds on fingernails without sacrificing other critical properties such as shine and wear resistance.